1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

17 Nov 2021
Admin
News Article

Gannex Gets China Nmpa Nod For Phase Ii And Iii Protocols Of Asc42 To Treat Primary Biliary Cholangitis

Gannex Pharma Co., Ltd., A Wholly Owned Company Of Ascletis Pharma Inc. Announces That The Protocols Of Phase Ii And Iii Clinical Trials Of Asc42 To Treat Patients With Primary Biliary Cholangitis (Pbc) Has Been Approved By China National Medical Products Administration (Nmpa).Pbc Is A New Chronic Hepatobiliary Disease Indication Approved For Clinical Trials Of Asc42. The Other Two Chronic Hepatobiliary Disease Indications Approved By China Nmpa And/Or Us Food And Drug Administration (Fda) Are Chronic Hepatitis B (Chb) And Non-Alcoholic Steatohepatitis (Nash).With The Approval Of Asc42 Pbc Phase Ii And Iii Protocols By China Nmpa, Gannex Is Expected To Complete The Phase Ii Trial In 100 Patients Who Have An Inadequate Response To Or Are Unable To Tolerate Ursodeoxycholic Acid (Udca). The Phase Ii Study Consists Of Three Active Treatment Arms And One Placebo Control Arm At The Ratio Of 1:1:1:1 And Is Expected To Complete In The Second Half Of 2022. Gannex Will Initiate The Phase Iii Trial After The Communications With China Nmpa In Terms Of Drug Registration Related Matters Such As Chemistry, Manufacturing And Control (Cmc) And Toxicology Studies.Asc42 Is An In-House Developed, Novel Non-Steroidal, Selective, Potent Farnesoid X Receptor (Fxr) Agonist With Best-In-Class Potential And Global Intellectual Property. The Data From The Us Phase I Trial Of Asc42 Indicated There Was No Pruritus Observed During 14-Day Treatment Of The Once-Daily Human Therapeutic Dose Of 15 Mg And Fxr Target Engagement Biomarker Fgf19 Increased 1,780% On Day 14 Of Treatment With 15 Mg Dose. Furthermore, Mean Ldl-C Values Remained Within The Normal Range During 14-Day, Once Daily Treatment With 15 Mg.Udca Is The Only Drug Which Is Approved In China For Pbc And Approximately 40% Pbc Patients Have An Inadequate Response To Or Are Unable To Tolerate Udca. Obeticholic Acid (Oca), Which Is Not Approved In China, Is The Only Approved Medicine In The Us For Pbc Patients Who Have An Inadequate Response To Or Are Unable To Tolerate Udca. However, There Are Significantly Increased Pruritus Rates And Ldl-C Levels In Patients With Oca Treatment. Lack Of Pruritus And Ldl-C Level Increase At The Therapeutic Dose Makes Asc42 A Potential Best-In-Class Pbc Drug. Gannex Intends To Start A Phase Iii Trial In The Us And European Union After The Completion Of The Phase Ii Study In China.Jidong Jia, Md, Director Of The Liver Disease Center, Beijing Friendship Hospital, Capital Medical University, Deputy Director Of National Clinical Research Center For Digestive Diseases, Stated,

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!